Loading stock data…
ABVC Biopharma, Inc. (ABVC)
$1.06+0.10 (+10.41%)
After Hours$1.06+0.00 (+0.00%)· Last close Sep 8
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ABVC BioPharma, Inc. in the Healthcare sector is trading at $1.06 with a market capitalization of $33M. The stock is currently near its 52-week low of $0.71, remaining 29.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0↑ | -$795,950 | $0 | $0 | $0 |
| Gross Profit | $0↑ | -$795,950 | $0 | $0 | $0 |
| Operating Income | -$1.57M↑ | -$2.99M↓ | -$1.96M↑ | -$2.29M↓ | -$693,005 |
| Net Income | -$1.56M↑ | -$3.56M↓ | -$2.04M↑ | -$2.26M↓ | -$842,075 |
Peer Comparison
JNJUNHPFE
Fundamentals
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therap...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$33.28M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.42
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-87.47%
Volume
Today's trading volume
151,759
